Dual inhibition of FLT3 and Akt-mediated signaling, such as that conferred by the multiple kinase inhibitor, KP372-1, has indeed been found to inhibit primary AML cell growth with minimal effect on normal progenitor cells [28]. Here, AKT1 is linked to acute myeloid leukemia.